KR20150057764A - Cosmetic composition containing Oriental Herb Fragrance Active Component Bornyl Acetate for Skin Benefit Ingredient - Google Patents
Cosmetic composition containing Oriental Herb Fragrance Active Component Bornyl Acetate for Skin Benefit Ingredient Download PDFInfo
- Publication number
- KR20150057764A KR20150057764A KR1020130141527A KR20130141527A KR20150057764A KR 20150057764 A KR20150057764 A KR 20150057764A KR 1020130141527 A KR1020130141527 A KR 1020130141527A KR 20130141527 A KR20130141527 A KR 20130141527A KR 20150057764 A KR20150057764 A KR 20150057764A
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- formula
- active ingredient
- compound
- compound represented
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 239000002537 cosmetic Substances 0.000 title claims abstract description 24
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 title abstract description 19
- 229940115397 bornyl acetate Drugs 0.000 title abstract description 9
- 239000004615 ingredient Substances 0.000 title description 13
- 239000003205 fragrance Substances 0.000 title description 10
- 230000008901 benefit Effects 0.000 title description 2
- 230000002087 whitening effect Effects 0.000 claims abstract description 44
- 230000037303 wrinkles Effects 0.000 claims abstract description 40
- 230000036560 skin regeneration Effects 0.000 claims abstract description 38
- 230000006872 improvement Effects 0.000 claims abstract description 36
- 235000013402 health food Nutrition 0.000 claims abstract description 15
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 107
- 239000000126 substance Substances 0.000 claims description 45
- 239000004480 active ingredient Substances 0.000 claims description 41
- 230000003078 antioxidant effect Effects 0.000 claims description 30
- 239000003963 antioxidant agent Substances 0.000 claims description 29
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 21
- 238000009472 formulation Methods 0.000 claims description 20
- 239000006071 cream Substances 0.000 claims description 19
- 239000006210 lotion Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 15
- -1 patch Substances 0.000 claims description 15
- 239000000499 gel Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- 239000002674 ointment Substances 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 7
- 239000003599 detergent Substances 0.000 claims description 6
- 239000000686 essence Substances 0.000 claims description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 34
- 206010061218 Inflammation Diseases 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 25
- 108010035532 Collagen Proteins 0.000 abstract description 22
- 102000008186 Collagen Human genes 0.000 abstract description 22
- 229920001436 collagen Polymers 0.000 abstract description 22
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract description 18
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 210000002950 fibroblast Anatomy 0.000 abstract description 8
- 150000003254 radicals Chemical class 0.000 abstract description 7
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 abstract 1
- 235000006708 antioxidants Nutrition 0.000 description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 27
- 238000004519 manufacturing process Methods 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000007796 conventional method Methods 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 12
- 239000000049 pigment Substances 0.000 description 11
- 235000013305 food Nutrition 0.000 description 10
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 10
- 239000003755 preservative agent Substances 0.000 description 10
- 229920002498 Beta-glucan Polymers 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 230000002335 preservative effect Effects 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 7
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 7
- 229930003268 Vitamin C Natural products 0.000 description 7
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 230000007760 free radical scavenging Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 235000019154 vitamin C Nutrition 0.000 description 7
- 239000011718 vitamin C Substances 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 229920001214 Polysorbate 60 Polymers 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 229960000271 arbutin Drugs 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 5
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 5
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 5
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 5
- 229940113124 polysorbate 60 Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical class OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 2
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000783 alginic acid Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Chemical class 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CNBGNNVCVSKAQZ-UHFFFAOYSA-N benzydamine Chemical compound C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 CNBGNNVCVSKAQZ-UHFFFAOYSA-N 0.000 description 2
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 2
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000011649 selenium Nutrition 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 229940091258 selenium supplement Drugs 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- KGEKLUUHTZCSIP-UHFFFAOYSA-N (1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl) acetate Chemical compound C1CC2(C)C(OC(=O)C)CC1C2(C)C KGEKLUUHTZCSIP-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 239000004475 Arginine Chemical class 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000521299 Deinocerites cancer Species 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015226 Erythema nodosum Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000002397 Kinins Human genes 0.000 description 1
- 108010093008 Kinins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical class SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical class CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical class NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical class CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical class [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical class OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229910000063 azene Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960000333 benzydamine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 125000003450 decanoic acid ester group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000012875 nonionic emulsifier Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical class CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037331 wrinkle reduction Effects 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
Description
본 발명은 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백용 조성물에 관한 것이다.
The present invention relates to a composition for skin regeneration, wrinkle improvement, antioxidation, anti-inflammation or skin whitening.
콜라겐은 피부의 섬유아세포에서 생성되는 주요 기질 단백질로서 세포외 간질에 존재하고, 중요한 기능으로는 피부의 기계적 견고성, 결합조직의 저항력과 조직의 결합력, 세포접착의 지탱, 세포분할과 분화(유기체의 성장 혹은 상처 치유시)의 유도 등이 알려져 있다. 이러한 콜라겐은 연령 및 자외선 조사에 의한 광 노화에 의해 감소하며, 이는 피부의 주름 형성과 밀접한 연관이 있다고 알려져 있다. 또한, 근래에 들어 피부 노화에 대한 광범위한 연구가 발전되면서 피부에서의 콜라겐의 중요한 기능이 밝혀지고 있다.Collagen is a major substrate protein produced in fibroblasts of the skin and exists in extracellular epilepsy. Its important functions are mechanical rigidity of skin, resistance of connective tissues and binding force of tissues, support of cell adhesion, division of cells and differentiation Growth or wound healing) are known. Such collagen is reduced by aging and photo aging caused by ultraviolet irradiation, which is known to be closely related to the wrinkling of the skin. Also, in recent years, extensive research on skin aging has developed, and important functions of collagen in skin have been revealed.
콜라겐 합성을 촉진하여 주름 개선 효과를 나타내는 유효성분들이 알려져 있다. 예를 들어, 레티노산(retinoic acid), TGF(transforming growth factor)[비특허문헌 1], 동물 태반 유래의 단백질[특허문헌 1], 베튤린산(betulinic acid)[특허문헌 2] 및 클로렐라 추출물[특허문헌 3, 4] 등이 콜라겐 합성 촉진 물질로서 알려져 있다. 그러나, 상기 유효성분들은 피부 적용 시 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 피부의 콜라겐 합성을 촉진하여 피부 기능을 개선하는 효과를 기대할 수 없는 문제점이 있다.Effective ingredients promoting collagen synthesis and exhibiting wrinkle-reducing effects are known. For example, retinoic acid, transforming growth factor (TGF) [Non-Patent Document 1], animal-derived placenta protein [Patent Document 1], betulinic acid [Patent Document 2] and chlorella extract [ Patent Documents 3 and 4] are known as collagen synthesis promoting substances. However, the above-mentioned effective ingredients are limited in the use amount due to safety problems such as irritation and redness when applied to the skin, or have insufficient effect, so that the effect of improving the skin function by promoting the collagen synthesis of the skin can not be expected.
한편, 생체 외부로부터 유입되거나, 생체 내에서 발생하는 활성 산소는 생체의 노화를 촉진시키거나, 암을 발생시키는 등 많은 문제의 원인이 된다. 따라서 활성 산소에 의한 산화를 억제하는 항산화 물질에 대한 개발 및 연구가 많이 이루어지고 있다. 항산화 물질은 동, 식물계에 널리 분포되어 있으며, 과일과 채소에 많이 함유되어 있는 페놀성 화합물, 플라보노이드, 토코페롤, 비타민 C, 셀레늄 등이 알려져 있다. 다만, 천연에 존재하는 항산화 물질은 피부 적용 시 실질적으로 충분한 효과를 기대할 수 없는 실정이다. 따라서, 항산화력이 뛰어나고 가격이 저렴한 합성 항산화제가 많이 사용되고 있으나, 인체 부작용 등 안전성에 대한 우려로 그 사용이 제한된다. On the other hand, active oxygen introduced from the outside of the living body or generated in the living body causes many problems such as promoting aging of the living body, cancer, and the like. Therefore, the development and research of antioxidants that inhibit oxidation by active oxygen have been performed. Antioxidants are widely distributed in copper and plants. Phenolic compounds, flavonoids, tocopherols, vitamin C, selenium and the like, which are widely contained in fruits and vegetables, are known. However, the antioxidant substances present in nature can not be expected to have practically sufficient effects in skin application. Therefore, although synthetic antioxidants having excellent antioxidant ability and low cost are widely used, their use is restricted due to safety concerns such as human side effects.
또한, 염증은 상처나 질병에 반응하는 인체의 면역 반응으로, 자외선이나 활성산소, 자유라디칼 등의 산화적 스트레스 등이 염증성 인자를 활성화시켜 각종 질병 및 피부의 노화를 일으킨다. 혈관 활성 폴리펩타이드인 키닌(kinin), 플라스민(plasmin) 또는 보체 (complement) 등이 혈관 확장과 수축 및 주화성(chemotaxis) 작용을 하고, 그 외에 인터루킨-6(IL-6) 등과 같은 림포카인과 아라키돈산(arachidonic acid) 등이 염증 반응을 담당한다. 아라키돈산은 싸이클로옥시게나아제(cyclooxygenase) 혹은 리포옥시게나아제(lipooxygenase)의 2가지 경로를 거쳐 염증 매개체인 프로스타글란딘(prostaglandin) 또는 류코트리엔(lukotriene)들로 대사되어 다양한 염증 반응을 매개한다. In addition, inflammation is an immune response of a human body in response to a wound or disease, and oxidative stress such as ultraviolet rays, active oxygen, free radicals, etc. activate inflammatory factors and cause aging of various diseases and skin. The vasoactive polypeptide, kinin, plasmin, or complement, has vasodilatation, contraction, and chemotaxis, as well as lymphokines such as interleukin-6 (IL-6) Phosphorus and arachidonic acid are responsible for inflammation. Arachidonic acid is metabolized through inflammatory mediators such as prostaglandin or lukotrienes via two pathways: cyclooxygenase or lipooxygenase, mediating a variety of inflammatory responses.
한편, 염증을 소실시키기 위해 염증원의 제거, 생체 반응 및 증상을 감소시키는 작용을 하는 것을 항염제라 한다. 현재까지 항염의 목적으로 이용되고 있는 물질로는 비스테로이드계로 플루폐나믹산(flufenamic acid), 이부프로펜(ibuprofen), 벤지다민(benzydamine) 또는 인도메타신(indomethacin) 등이 있고 스테로이드계통으로 프레드니솔론(prednisolone) 또는 덱사메타손 (dexamethasone) 등이 있다. 또한 알란토인, 아즈엔 또는 하이드로코티손 등이 항염증에 효과가 있는 것으로 알려져 있으나, 이들 물질은 피부에 대한 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적으로 염증 완화 효과를 기대할 수 없는 문제점이 있다.On the other hand, in order to eliminate inflammation, elimination of inflammation source, reduction of vital reaction and symptoms is called anti-inflammatory. To date, substances used for antiinflammatory purposes include non-steroidal drugs such as flufenamic acid, ibuprofen, benzydamine or indomethacin, prednisolone in the steroid line, Or dexamethasone. It is also known that allantoin, azene or hydrocortisone are effective for anti-inflammation. However, these substances have a problem that they can not be expected to effectively reduce the inflammation because of their limited use due to the safety of the skin, have.
또한, 희고 고운 피부를 갖고자 하는 것은 일반적인 소망이다. 피부의 색깔 또는 밝기는 사람의 피부 내 멜라닌(melanin)의 농도와 분포에 따라 유전적으로 결정되나, 태양 자외선, 피로 또는 스트레스 등의 환경적 또는 생리적 조건에 의해서도 영향을 받는다. 멜라닌은 아미노산의 일종인 티로신(tyrosine)에 티로시나제(tyrosinase)라는 효소가 촉매로 작용하여 도파(DOPA) 및 도파퀴논(dopaquinone)으로 순차적으로 바뀐 후, 비효소적인 산화반응을 거쳐 만들어진다. 이와 같이 멜라닌이 만들어지는 경로는 알려져 있으나, 멜라닌 합성을 유도하는 메커니즘에서 티로시나제가 촉발되는 원인이 무엇인지에 대해서는 아직도 자세히 밝혀지지 않고 있다. In addition, it is a common desire to have white skin. The color or brightness of the skin is genetically determined by the concentration and distribution of melanin in the human skin but is also influenced by environmental or physiological conditions such as sunlight, fatigue or stress. Melanin is produced by a nonenzymatic oxidation reaction in which tyrosine, an amino acid, is catalyzed by an enzyme called tyrosinase, which is subsequently converted to dopa (DOPA) and dopaquinone. The pathway for the formation of melanin is known, but the mechanism by which the melanin synthesis induces tyrosinase is not yet elucidated.
한편, 일반적으로 알려진 미백 성분으로서, 코지산(Kojic acid) 또는 알부틴(Arbutin) 등과 같은 티로시나제 효소활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민 C(L-Ascorbic acid) 또는 이들의 유도체와 각종 식물 추출물이 있다. 이들은 멜라닌 색소의 합성을 저해함으로써, 피부 톤을 밝게 하여 피부 미백을 실현할 수 있을 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착증의 개선이 가능하다. 그러나 피부 적용 시, 자극과 발적 등의 안전성의 문제로 사용량의 제한이 있거나, 효과가 미미하여 실질적인 효과를 기대할 수 없는 문제점이 있다. On the other hand, commonly known whitening ingredients include substances inhibiting the activity of tyrosinase enzymes such as kojic acid or arbutin, hydroquinone, vitamin C (L-ascorbic acid) There are plant extracts. By inhibiting the synthesis of melanin pigment, they can brighten the skin tone to realize skin whitening, and it is possible to improve skin hypercholesterolemia such as stain or freckles due to ultraviolet rays, hormones or heredity. However, when applied to skin, there is a problem that the use amount is limited due to safety problems such as irritation and redness, or the effect is insignificant, so that a practical effect can not be expected.
따라서, 생체에 안전하고, 유효성분이 안정하며, 무엇보다도 기존의 피부 재생, 주름개선, 항산화, 항염증 또는 미백 효과가 있는 물질보다 효과가 우수한 피부 재생, 주름개선, 항산화, 항염증 또는 미백 활성을 지닌 성분의 개발이 절실히 요망되고 있다.
Accordingly, it is possible to provide a method for improving the skin regeneration, wrinkle improvement, antioxidant, anti-inflammatory or whitening activity, which is more safe and effective in the living body, more effective than the substance having existing skin regeneration, wrinkle improvement, antioxidant, anti- It is urgently required to develop a component having an amino acid sequence.
[선행문헌][Prior Art]
[특허문헌][Patent Literature]
(특허문헌 0001) 일본 특개 평8-231370호 (Patent Document 0001) Japanese Patent Application Laid-Open No. 8-231370
(특허문헌 0002) 일본 특개 평8-208424호(Patent Document 0002) Japanese Patent Application Laid-Open No. 8-208424
(특허문헌 0003) 일본 특개 평9-40523호(Patent Document 0003) Japanese Patent Application Laid-Open No. 9-40523
(특허문헌 0004) 일본 특개 평10-36283호
(Patent Document 0004) Japanese Patent Application Laid-Open No. 10-36283
[비특허문헌][Non-Patent Document]
(비특허문헌 0001) Cardinale G. et al, Adv. Enzymol., 41, p. 425, 1974
(Non-Patent Document 0001) Cardinale G. et al, Adv. Enzymol., 41, p. 425, 1974
이에, 본 발명자들은 보닐아세테이트(bornyl acetate)가 피부의 섬유아세포의 콜라겐 총량을 증가시켜 피부의 재생을 촉진시키고 주름을 개선하며, 자유 라디칼을 소거하여 항산화 효과를 나타내고, 산화질소(NO) 생성을 억제하여 항염증 효과를 나타내며, 멜라닌 총량이 현저히 감소하여 미백 효과를 나타내는 것을 확인하고 본 발명을 완성하게 되었다.Accordingly, the present inventors have found that bornyl acetate increases the total amount of collagen in skin fibroblasts, thereby promoting skin regeneration, improving wrinkles, eliminating free radicals, exhibiting antioxidative effects, And exhibited an anti-inflammatory effect. The total amount of melanin was markedly decreased to show a whitening effect, and the present invention was completed.
따라서, 본 발명의 목적은 하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백용 조성물을 제공하는데 있다:Accordingly, an object of the present invention is to provide a composition for skin regeneration, wrinkle improvement, antioxidation, anti-inflammation or skin whitening comprising a compound represented by the following formula 1 as an active ingredient:
[화학식 1][Chemical Formula 1]
상기 과제를 해결하기 위한 수단으로서, 본 발명은As means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백용 약학적 조성물을 제공한다.There is provided a pharmaceutical composition for skin regeneration, wrinkle improvement, antioxidation, anti-inflammation or skin whitening comprising a compound represented by the following formula (1) as an active ingredient.
[화학식 1] [Chemical Formula 1]
상기 과제를 해결하기 위한 다른 수단으로서, 본 발명은 As another means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백용 피부 외용제를 제공한다.There is provided a skin external preparation for skin regeneration, wrinkle improvement, antioxidation, anti-inflammation or skin whitening comprising a compound represented by the following formula (1) as an active ingredient.
[화학식 1][Chemical Formula 1]
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은As another means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백용 화장료 조성물을 제공한다.There is provided a cosmetic composition for skin regeneration, wrinkle improvement, antioxidant, anti-inflammation or skin whitening comprising a compound represented by the following formula (1) as an active ingredient.
[화학식 1][Chemical Formula 1]
상기 과제를 해결하기 위한 또 다른 수단으로서, 본 발명은As another means for solving the above problems,
하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백용 건강식품을 제공한다.There is provided a health food for skin regeneration, wrinkle improvement, antioxidant, anti-inflammation or skin whitening comprising a compound represented by the following formula (1) as an active ingredient.
[화학식 1][Chemical Formula 1]
본 발명에 따른 보닐아세테이트(bornyl acetate)는 피부의 섬유아세포의 콜라겐 총량을 증진시켜, 피부의 재생을 촉진시키며, 자유 라디칼을 소거하여 항산화 효과를 나타내고, 염증 반응에 관여하는 산화질소(NO) 생성을 억제하여 항염증 효과가 뛰어나며, 멜라닌 총량을 현저히 감소하여 미백 효과를 나타냄으로써 의약품, 화장료 또는 건강식품에 사용할 수 있다.
The bornyl acetate according to the present invention promotes the regeneration of the skin by promoting the total amount of collagen of the fibroblasts of the skin, and exhibits antioxidative effect by scavenging free radicals, and produces nitric oxide (NO) And excellent antiinflammatory effect. The total amount of melanin is markedly reduced to exhibit a whitening effect, so that it can be used in medicines, cosmetics or health foods.
이하, 본 발명의 구성을 구체적으로 설명한다.Hereinafter, the configuration of the present invention will be described in detail.
피부 재생, 주름 개선, 항산화, 항염증 또는 미백 성분이 실제 피부에 적용 시 우수한 효과를 발휘하기 위해서는 저농도에서 고활성의 피부 재생, 주름개선, 항산화, 항염증 또는 미백 활성을 나타내고, 피부를 투과하여 흡수되는 능력이 우수한 것이 바람직하다. 또한 피부 재생, 주름 개선, 항산화, 항염증 또는 미백 효과를 나타내기에 충분한 시간 동안 머무를 수 있도록 휘발성이 낮으며, 조성물이나 피부 상에서 활성 성분이 안정하게 유지되고, 의약이나 화장품으로의 제형화가 용이하며, 또한 피부에 안전한 것이 바람직하다. 그러나 공지의 성분 중 상기 특성을 모두 만족시키는 성분은 흔치 않다. 예를 들어, 몇몇 피부 재생, 주름 개선, 항산화, 항염증 또는 미백 성분들은 시험관 내 실험 시 저농도에서도 피부 재생, 주름 개선, 항산화, 항염증 또는 미백 활성은 우수하나, 피부를 투과하여 흡수되는 능력이 떨어져 실제 피부에 적용하기엔 어렵다. 또 다른 활성 성분들은 친수성이 낮아 의약이나 화장품으로 제형화가 어렵다. 또한, 몇몇 피부 재생, 주름 개선, 항산화, 항염증 또는 미백 성분들은 열, 광, 또는 산소에 노출되었을 때 상기 활성 성분이 분해되거나 다른 화합물로 변형되어 피부에 적용하기 전에 이미 효과가 사라지는 경우도 있다. In order to exert excellent effects when the skin regeneration, wrinkle improvement, antioxidant, anti-inflammation or whitening ingredient is applied to the actual skin, it exhibits high activity of skin regeneration, wrinkle improvement, antioxidant, anti-inflammatory or whitening activity at a low concentration, It is preferable that the ability to be absorbed is excellent. Also, it has low volatility so that it can stay for a sufficient time to exhibit skin regeneration, wrinkle improvement, antioxidant, anti-inflammatory or whitening effect, and the active ingredient remains stable on the composition or skin, It is also preferred that it is skin-safe. However, among the known components, the components satisfying all of the above characteristics are not common. For example, some skin regeneration, wrinkle improvement, antioxidant, anti-inflammatory or whitening ingredients are excellent in skin regeneration, wrinkle improvement, antioxidant, anti-inflammatory or whitening activity even at low concentration in in vitro test, It is difficult to apply to real skin. Other active ingredients have low hydrophilicity and are difficult to formulate into medicines or cosmetics. In addition, some skin regeneration, wrinkle improvement, antioxidant, anti-inflammatory or whitening ingredients may be degraded or transformed into other compounds when exposed to heat, light, or oxygen, .
하기 실시예에서 확인할 수 있는 바와 같이, 보닐아세테이트(bornyl acetate)는 콜라겐 총량이 월등히 증가하는 효과, 멜라닌 총량이 현저히 감소하는 효과, 자유라디칼 소거율이 우수한 효과, 산화질소 생성 억제 효과를 나타내므로 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백을 위한 의약품, 화장료 또는 건강식품 등의 유효성분으로 사용할 수 있다. As can be seen in the following examples, bornyl acetate exhibits a remarkable effect of increasing the total amount of collagen, a significant reduction in the total amount of melanin, an excellent effect of free radical scavenging rate, And can be used as an active ingredient for medicines, cosmetics, or health food for regeneration, wrinkle improvement, antioxidation, anti-inflammation or skin whitening.
따라서, 본 발명은 하기 화학식 1로 표현되는 화합물을 유효성분으로 포함하는 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백용 약학적 조성물을 제공한다.Accordingly, the present invention provides a pharmaceutical composition for skin regeneration, wrinkle improvement, antioxidation, anti-inflammation or skin whitening comprising a compound represented by the following formula (1) as an active ingredient.
[화학식 1][Chemical Formula 1]
상기 화학식 1의 화합물은 일명 보닐아세테이트(bornyl acetate)라 하며, 가능한 모든 이성체를 포함할 수 있다.The compound of Formula 1 is called bornyl acetate and may include all possible isomers.
상기 화학식 1의 화합물은 합성하여 이용하거나, 시판되고 있는 화합물을 이용할 수 있다. The compound of formula (1) may be synthesized or a commercially available compound may be used.
본 발명의 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백용 약학적 조성물은 상기 화학식 1의 화합물의 약제학적으로 허용 가능한 염을 포함할 수 있다.The pharmaceutical composition for skin regeneration, wrinkle improvement, antioxidation, anti-inflammation or skin whitening of the present invention may comprise a pharmaceutically acceptable salt of the compound of formula (1).
상기 화학식 1의 화합물의 약제학적으로 허용 가능한 염은 유기산 또는 무기산을 이용하여 형성된 산 부가염일 수 있으며, 상기 유기산은 예를 들면 포름산, 아세트산, 프로피온산, 락트산, 부티르산, 이소부티르산, 트리플루오로아세트산, 말산, 말레산, 말론산, 푸마르산, 숙신산, 숙신산 모노아미드, 글루탐산, 타르타르산, 옥살산, 시트르산, 글리콜산, 글루쿠론산, 아스코르브산, 벤조산, 프탈산, 살리실산, 안트라닐산, 디클로로아세트산, 아미노옥시 아세트산, 벤젠술폰산, p-톨루엔술폰산 또는 메탄술폰산계 염을 포함한다. 무기산은 예를 들면 염산, 브롬산, 황산, 인산, 질산, 탄산 또는 붕산계 염을 포함한다. 바람직하게는 염산염 또는 아세트산염 형태일 수 있으며, 보다 바람직하게는 염산염 형태일 수 있다.The pharmaceutically acceptable salt of the compound of Chemical Formula 1 may be an acid addition salt formed using an organic acid or an inorganic acid, and examples of the organic acid include formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, The present invention also relates to the use of a compound selected from the group consisting of malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, gluconic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, Benzenesulfonic acid, p-toluenesulfonic acid or methanesulfonic acid-based salts. The inorganic acid includes, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid or boric acid-based salts. Preferably in the hydrochloride or acetate form, more preferably in the hydrochloride form.
상기 언급된 산 부가염은 a) 상기 화학식 1의 화합물 및 산을 직접 혼합하거나, b) 이들 중 한 가지를 용매 또는 함수 용매 중에 용해시키고 혼합시키거나, 또는 c) 화학식 1의 화합물을 용매 또는 수하 용매 중의 산에 위치시키고 이들을 혼합하는 일반적인 염 제조방법으로 제조된다.The above-mentioned acid addition salts may be obtained by a) directly mixing the compound of formula 1 and an acid, or b) dissolving and mixing one of them in a solvent or a water solvent, or c) Lt; RTI ID = 0.0 > acid < / RTI > in a solvent and mixing them.
위와는 별도로 추가적으로 염이 가능한 형태는 가바염, 가바펜틴염, 프레가발린염, 니코틴산염, 아디페이트염, 헤미말론산염, 시스테인염, 아세틸시스테인염, 메티오닌염, 아르기닌염, 라이신염, 오르니틴염 또는 아스파르트산염 등이 있다.
Separately, additionally saltable forms include, but are not limited to, the salts of gabapentin, gabapentin, pregabalin, nicotinate, adipate, hemimarate, cysteine, acetylcysteine, methionine, arginine, lysine, Aspartate and the like.
또한, 본 발명의 상기 화학식 1의 화합물을 의약품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백 성분을 포함할 수 있을 것이다. 추가적인 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백 성분을 포함하게 되면 본 발명의 조성물의 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백 효과는 더욱 증진될 수 있을 것이다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 본 발명의 한 구체예에서, 상기 조성물은 당업계에 공지된 피부 재생 성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베튤린산 또는 클로렐라 추출물; 당업계에 공지된 항산화 성분으로서, 토코페롤, 셀레늄, 비타민 C 또는 페놀성 화합물; 당업계에 공지된 미백 성분으로서, 코지산(Kojic acid) 또는 알부틴(Arbutin) 등과 같은 티로시나제 효소활성을 억제하는 물질, 하이드로퀴논(Hydroquinone), 비타민-C(L-Ascorbic acid), 이들의 유도체 및 각종 식물 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 성분을 추가로 포함할 수 있다. 추가의 성분은 전체 조성물 중량에 대하여 0.0001 중량% 이상 내지 10 중량% 이하로 포함될 수 있다. 예를 들어, 0.0001 중량% 이상 내지 1 중량% 이하, 0.0001중량% 이상 내지 0.1중량% 이하, 0.0001 중량% 이상 내지 0.001 중량% 이하, 0.001중량% 이상 내지 10중량% 이하, 0.001중량% 이상 내지 1중량% 이하, 0.001 중량% 이상 내지 0.1중량% 이하, 0.01 중량% 이상 내지 10중량% 이하, 0.01중량% 이상 내지 1 중량% 이하일 수 있다. 상기 함량 범위는 피부 안전성, 상기 화학식 1의 화합물의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있을 것이다.When the compound of Chemical Formula 1 of the present invention is used as a medicine, it may further contain one or more active ingredients showing the same or similar functions. For example, it may contain known skin regeneration, wrinkle reduction, antioxidant, anti-inflammatory or skin whitening ingredients. The skin regeneration, wrinkle improvement, antioxidant, anti-inflammation or skin whitening effect of the composition of the present invention may be further enhanced if the skin regeneration, wrinkle improvement, antioxidant, anti-inflammation or skin whitening component is included. When the above ingredients are added, skin safety, easiness of formulation, and stability of effective ingredients can be considered according to the combined use. In one embodiment of the invention, the composition is a skin regeneration component known in the art comprising retinoic acid, TGF, protein from animal placenta, betulinic acid or chlorella extract; Antioxidant components known in the art include tocopherol, selenium, vitamin C or phenolic compounds; Examples of whitening ingredients known in the art include substances inhibiting tyrosinase enzyme activity such as kojic acid or arbutin, hydroquinone, L-ascorbic acid, derivatives thereof, And various plant extracts. The composition of the present invention may further comprise one or more components selected from the group consisting of plant extracts. The additional component may be contained in an amount of 0.0001 wt% to 10 wt% based on the total weight of the composition. For example, from 0.0001 wt% to 1 wt%, from 0.0001 wt% to 0.1 wt%, from 0.0001 wt% to 0.001 wt%, from 0.001 wt% to 10 wt%, from 0.001 wt% 0.001 wt% or more to 0.1 wt% or less, 0.01 wt% or more to 10 wt% or less, or 0.01 wt% or more to 1 wt% or less. The content range may be adjusted according to requirements such as skin safety, ease of formulation of the compound of Formula 1, and the like.
또한, 본 발명의 피부 재생, 주름개선, 항산화, 항염증 또는 피부 미백용 약학적 조성물은 약학적으로 허용 가능한 담체를 더 포함할 수 있다.In addition, the pharmaceutical composition for skin regeneration, wrinkle improvement, antioxidation, anti-inflammation or skin whitening of the present invention may further comprise a pharmaceutically acceptable carrier.
약학적으로 허용되는 담체는 완충액, 주사용 멸균수, 일반 식염수 또는 인산염 완충 식염수, 슈크로스, 히스티딘, 또는 폴리솔베이트 등과 같은 여러 성분을 함유할 수 있다.Pharmaceutically acceptable carriers may contain various components such as buffer, injectable sterile water, normal saline or phosphate buffered saline, sucrose, histidine, or polysorbate.
본 발명의 약학적 조성물은 경구 또는 비경구로 투여할 수 있으며, 일반 의약품 제제의 형태, 예를 들어, 임상 투여 시 경구 또는 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제 또는 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.The pharmaceutical composition of the present invention can be administered orally or parenterally, and can be administered in the form of a general pharmaceutical preparation, for example, in a variety of oral or parenteral formulations upon clinical administration. In the case of formulation, , Extenders, binders, wetting agents, disintegrating agents, or surfactants.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제 또는 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 약학적 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(Calcium carbonate), 수크로스(Sucrose), 락토오스(Lactose) 또는 젤라틴 등을 섞어 조제될 수 있다.Solid form preparations for oral administration include tablets, pills, powders, granules or capsules, which may be prepared by mixing the pharmaceutical composition of the present invention with at least one excipient such as starch, calcium carbonate, Sucrose, lactose, gelatin, and the like.
단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제 또는 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물 또는 리퀴드 파라핀 이외에 여러가지 부형제, 예를 들면 습윤제, 감미제, 방향제 또는 보존제 등이 포함될 수 있다.In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions or syrups. In addition to water or liquid paraffin, which is a simple diluent commonly used, various excipients such as wetting agents, sweetening agents, fragrances or preservatives may be included.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제 또는 좌제가 포함된다. 비수성용제 또는 현탁용제로는 프로필렌 글리콜(Propylene glycol), 폴리에틸렌 글리콜 또는 올리브 오일과 같은 식물성 기름; 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지 또는 글리세로제라틴 등이 사용될 수 있다.
Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations or suppositories. Non-aqueous vehicles or suspending agents include vegetable oils such as propylene glycol, polyethylene glycol or olive oil; And injectable esters such as ethyl oleate may be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao paper, laurin or glycerogelatin can be used.
본 발명에 있어서, "피부 재생 효과"라 함은 피부 외부 및 내부 원인에 의한 손상에 대하여 피부 조직이 회복되는 것을 말한다. 상기 외부 원인에 의한 손상은 자외선, 외부 오염 물질, 창상 또는 외상 등을 들 수 있으며, 상기 내부 원인에 의한 손상은 스트레스 등을 들 수 있다.In the present invention, "skin regeneration effect" refers to restoration of skin tissue against damage caused by external or internal causes of the skin. The damage caused by the external cause may be ultraviolet rays, external contaminants, wound or trauma, and the damage caused by the internal cause may be stress.
본 발명에 있어서, "주름개선 효과"라 함은 피부에 주름이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 주름을 완화시키는 것을 말한다. In the present invention, the term "wrinkle-reducing effect" refers to inhibiting or inhibiting the generation of wrinkles on the skin, or alleviating wrinkles already generated.
본 발명에 있어서, "항산화 효과"라 함은 세포 내 대사 또는 자외선의 영향으로 인한 산화적 스트레스에 따라 반응성이 높은 자유 라디칼(free radical) 또는 활성산소종(reactive oxygen species;ROS)에 의한 세포의 산화를 억제하는 것을 말하며, 자유 라디칼 또는 활성산소종을 제거하여 이로 인한 세포의 손상이 감소되는 것을 포함한다.In the present invention, the term "antioxidative effect" refers to the action of free radicals or reactive oxygen species (ROS) due to oxidative stress caused by intracellular metabolism or ultraviolet rays Refers to inhibition of oxidation, and includes removal of free radical or reactive oxygen species, thereby reducing damage to the cells.
본 발명에 있어서, "항염증 효과"라 함은 염증을 억제하는 것을 말한다. 상기 염증은 어떤 자극에 대한 생체조직의 방어반응의 하나로, 조직 변질, 순환 장애와 삼출 및 조직 증식의 세가지를 병발하는 복잡한 병변을 말한다. 보다 구체적으로 염증은 선천성 면역의 일부이며 다른 동물에서처럼 인간의 선천성 면역은 병원체에 특이적으로 존재하는 세포 표면의 패턴을 인식한다. 식세포는 그런 표면을 가진 세포를 비자기로 인식하고 병원체를 공격한다. 만일 병원균이 신체의 물리적 장벽을 깨고 들어온다면 염증반응이 일어난다. 염증반응은 상처부위에 침입한 미생물들에 대한 적대 환경을 만드는 비특이적인 방어작용이다. 염증반응에서, 상처가 나거나 외부 감염체가 체내로 들어왔을 때, 초기단계 면역반응을 맡고 있는 백혈구들이 몰려들어 사이토카인을 발현한다. 따라서 세포 내 사이토카인의 발현양이 염증반응 활성화의 지표가 된다. 염증과 관련된 피부질환의 예로는 아토피 피부염, 건선, 방사선, 화학물질 또는 화상 등에 의한 홍반성 질환; 산 화상, 수포성 피부병, 태선 모양 종류 질환 또는 알레르기 등에 의한 가려움증; 지루성 습진, 장미 여드름, 심상성 천포창, 다형 삼출성 홍반, 결절 홍반, 귀두염, 음문염 또는 원형 탈모증과 같은 염증성 모발 손실; 피부 T-세포 림프종 등이 있으나 이에 제한되는 것은 아니다.In the present invention, "anti-inflammatory effect" refers to inhibiting inflammation. The inflammation is one of biological tissue defense responses to stimulation, and refers to complicated lesions involving tissue degeneration, circulatory disorder, exudation and tissue proliferation. More specifically, inflammation is part of congenital immunity and, like in other animals, human congenital immunity recognizes a pattern of cell surfaces that are specifically present in a pathogen. Phagocytes recognize cells with such surfaces as non-magnetic and attack pathogens. If pathogens break through the physical barriers of the body, an inflammatory reaction occurs. Inflammation is a nonspecific defense that creates hostile environments for microorganisms entering the wound. In the inflammatory response, white blood cells that are responsible for the early stage of immune response, when wounded or infected, enter the body to express cytokines. Therefore, the expression level of intracellular cytokine is an index of inflammatory response activation. Examples of skin diseases associated with inflammation include, but are not limited to, atopic dermatitis, psoriasis caused by psoriasis, radiation, chemicals or burns; Itching caused by acid burns, watery skin diseases, psoriasis type diseases or allergies; Inflammatory hair loss such as seborrhoeic eczema, rose acne, pemphigus pemphigus, polymorphous exudative erythema, erythema nodosum, acuminate, pharyngitis or alopecia areata; Skin T-cell lymphoma, and the like.
본 발명에 있어서, "미백 효과"라 함은 멜라닌 색소의 합성을 저해함으로써 피부 톤을 밝게 할 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 말한다.In the present invention, the term " whitening effect "refers to not only brightening the skin tone by inhibiting the synthesis of melanin pigment but also improving skin hypercholesterolemia due to ultraviolet rays, hormones or heredity, such as spots or freckles.
본 발명의 약학적 조성물은 유효량의 상기 화학식 1의 화합물을 포함할 때 바람직한 피부 재생, 주름 개선, 항산화, 항염증 또는 미백 등의 효과를 제공할 수 있다. 본 발명에 있어서, '유효량'이라 함은 손상된 피부의 재생을 촉진하거나, 주름을 개선하거나, 세포의 산화를 억제 또는 완화하거나, 염증을 억제하거나, 미백효과를 나타낼 수 있는 화합물의 양을 의미한다. 본 발명의 조성물에 포함되는 상기 화학식 1의 화합물의 유효량은 조성물이 제품화되는 형태, 상기 화합물이 피부에 적용되는 방법 또는 피부에 머무르는 시간 등에 따라 달라질 것이다. 예컨대, 상기 조성물이 의약품으로 제품화되는 경우에는 일상적으로 피부에 적용하게 되는 화장품으로 제품화되는 경우에 비해 높은 농도로 상기 화학식 1의 화합물을 포함할 수 있을 것이다. 따라서, 일일 투여량은 상기 화학식 1의 화합물의 양을 기준으로 0.1 내지 100 ㎎/㎏이고, 바람직하게는 30 내지 80 ㎎/㎏이고, 더욱 바람직하게는 50 내지 60 mg/kg이며, 하루 1 ∼ 6 회 투여될 수 있다. The pharmaceutical composition of the present invention can provide effects such as skin regeneration, wrinkle improvement, antioxidation, anti-inflammation or whitening when the compound of Chemical Formula 1 is contained in an effective amount. In the present invention, the term "effective amount" means an amount of a compound capable of promoting regeneration of damaged skin, improving wrinkles, inhibiting or alleviating oxidation of cells, suppressing inflammation, or exhibiting a whitening effect . The effective amount of the compound of formula (1) contained in the composition of the present invention will vary depending on the form in which the composition is commercialized, the method in which the compound is applied to the skin or the time on the skin. For example, when the composition is commercialized as a pharmaceutical product, the compound of Formula 1 may be contained at a higher concentration than that of a cosmetic product that is routinely applied to skin. Accordingly, the daily dosage is 0.1 to 100 mg / kg, preferably 30 to 80 mg / kg, more preferably 50 to 60 mg / kg, based on the amount of the compound of formula (1) 6 times a day.
본 발명의 약학적 조성물은 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 또는 생물학적 반응조절제를 사용하는 방법들과 병용하여 사용할 수 있다.
The pharmaceutical compositions of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy or biological response modifiers.
본 발명은 또한 상기 화학식 1의 화합물을 유효성분으로 포함하는 피부 재생, 주름개선, 항산화, 항염증 또는 미백용 피부 외용제의 제형으로 제공할 수 있다.The present invention can also be provided as a formulation of a skin external preparation for skin regeneration, wrinkle improvement, antioxidation, anti-inflammation or whitening comprising the compound of Formula 1 as an active ingredient.
상기 화학식 1의 화합물을 피부외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 유화제, 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 활성제, 친유성 활성제 또는 지질 소낭 등 피부 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다. When the compound of formula (1) is used as an external preparation for skin, it may further comprise at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, Such as water, an ionic emulsifier, a nonionic emulsifier, a filler, a sequestering agent, a chelating agent, a preservative, a vitamin, a blocker, a wetting agent, a necessary oil, a dye, a pigment, a hydrophilic activator, Such as any other ingredients conventionally used in the field of skin science. The components can also be introduced in amounts commonly used in the field of dermatology.
상기 화학식 1의 화합물이 피부 외용제로 제공될 경우, 이에 제한되는 것은 아니나, 연고, 패취, 겔, 크림 또는 분무제 등의 제형일 수 있다.
When the compound of Formula 1 is provided as an external preparation for skin, it may be a formulation such as ointments, patches, gels, creams or sprays.
본 발명은 또한 상기 화학식 1의 화합물을 유효성분으로 포함하는 피부 재생, 주름개선, 항산화, 항염증 또는 미백용 화장료의 제형으로 제공할 수 있다.The present invention can also be provided as formulations of skin regeneration, wrinkle improvement, antioxidant, anti-inflammatory or whitening cosmetic compositions containing the compound of Formula 1 as an active ingredient.
상기 화학식 1의 화합물을 화장품으로 사용하는 경우, 상기 화학식 1의 화합물을 유효성분으로 함유하여 제조되는 화장품은 일반적인 유화 제형 또는 가용화 제형의 형태로 제조할 수 있다. 예컨대, 유연 화장수 또는 영양 화장수 등과 같은 화장수; 훼이셜 로션 또는 바디로션 등과 같은 유액; 영양 크림, 수분 크림 또는 아이 크림 등과 같은 크림; 에센스; 화장연고; 스프레이; 젤; 팩; 선 스크린; 메이크업 베이스; 액체 타입, 고체 타입 또는 스프레이 타입 등의 파운데이션; 파우더; 클렌징 크림, 클렌징 로션, 클렌징 오일과 같은 메이크업 제거제; 클렌징 폼, 비누, 바디 워쉬 등과 같은 세정제 등의 제형을 가질 수 있다. When the compound of Chemical Formula 1 is used as a cosmetic, the cosmetic product containing the compound of Chemical Formula 1 as an active ingredient may be prepared in the form of a general emulsion or solubilized formulation. Lotion such as soft lotion or nutrition lotion; Lotion such as facial lotion or body lotion; Creams such as nutritional creams, moisture creams or eye creams; essence; Makeup ointment; spray; Gel; pack; Sunscreen; Makeup base; A foundation such as a liquid type, a solid type or a spray type; powder; Makeup removers such as cleansing creams, cleansing lotions, cleansing oils; Detergents such as cleansing foams, soaps, body wash, and the like.
또한 상기 화장품은 상기 화학식 1의 화합물에 추가로 지방 물질, 유기 용매, 용해제, 농축제, 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 유화제, 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 활성제, 친유성 활성제 또는 지질 소낭 등 화장품 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.The cosmetic composition may further contain, in addition to the compound of Formula 1, a lipid, an organic solvent, a solubilizing agent, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, The present invention is generally applied to cosmetics such as ionic emulsifiers, nonionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic active agents, lipophilic active agents, And may contain auxiliary agents used.
상기 화학식 1의 화합물은 화장품으로 제품화되는 경우에 유효성분이 단기간 내에 피부에 머무르게 되는 메이크업 제거제 또는 세정제와 같은 워쉬-오프(wash-off) 타입의 화장품의 경우에는 비교적 높은 농도의 상기 화학식 1의 화합물을 포함할 수 있을 것이다. 반면, 유효성분이 장기간 피부에 머무르게 되는 화장수, 유액, 크림 또는 에센스 등의 리브-온(leave-on) 타입의 화장품의 경우에는 워쉬-오프 타입의 화장품에 비해 낮은 농도의 상기 화학식 1의 화합물을 포함해도 무방할 것이다. 이에 제한되는 것은 아니나, 본 발명의 한 구체예에서, 상기 조성물은 상기 화학식 1의 화합물을 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%(바람직하게는 0.0001 중량% 내지 1 중량%)로 포함할 수 있다. 본 발명의 조성물이 상기 화학식 1의 화합물을 0.0001 중량% 미만으로 포함할 경우에는 충분한 피부 재생, 주름개선, 항산화, 항염증 또는 미백 효과를 기대할 수 없고, 10 중량%를 초과하여 포함할 경우에는 알러지 등 원치 않는 반응이 발생하거나 피부 안전성에 문제가 있을 수 있으므로 이를 방지하기 위한 것이다.
In the case of a wash-off type cosmetic such as a make-up removing agent or a detergent in which the active ingredient remains on the skin in a short period of time when the compound of formula (1) is commercialized, a relatively high concentration of the compound of formula . On the other hand, in the case of a leave-on type cosmetics such as lotion, milk, cream or essence whose effective ingredient remains on the skin for a long period of time, the compound of the above formula 1 is contained at a lower concentration than that of the wash- It may be possible. In one embodiment of the present invention, although not limited thereto, the composition may contain 0.0001 wt% to 10 wt% (preferably 0.0001 wt% to 1 wt%) of the compound of Formula 1 based on the total weight of the composition . When the composition of the present invention contains less than 0.0001% by weight of the compound of Formula 1, sufficient skin regeneration, wrinkle improvement, antioxidant, anti-inflammatory or whitening effect can not be expected. When the composition contains more than 10% To prevent unwanted reactions or skin safety problems.
본 발명은 또한 상기 화학식 1의 화합물을 포함하는 피부 재생, 주름개선, 항산화, 항염증 또는 미백용 건강식품에 관한 것이다.The present invention also relates to a skin regeneration, wrinkle improvement, antioxidant, anti-inflammatory or whitening health food containing the compound of the above formula (1).
본 명세서에서 "건강식품"이란, 상기 화학식 1의 화합물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 이를 섭취할 경우 건강상 특정한 효과를 가져오는 것을 의미하나, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용이 없는 장점이 있다.Herein, the term "health food" means a food prepared by adding the compound of formula (1) to food materials such as beverage, tea, spice, gum and confectionery, or by encapsulation, powdering or suspension, But it has the advantage that there is no side effect that can occur when a drug is taken for a long time using a food as a raw material, unlike a general medicine.
이와 같이 하여 얻어지는 본 발명의 건강식품은, 일상적으로 섭취하는 것이 가능하기 때문에 높은 피부 재생, 주름개선, 항산화, 항염증 또는 미백 효과를 기대할 수 있어 매우 유용하다.The health food of the present invention obtained as described above is very useful because it can be taken on a daily basis and can be expected to have high skin regeneration, wrinkle improvement, antioxidant, anti-inflammatory or whitening effect.
상기 화학식 1의 화합물을 식품첨가물로 사용하는 경우, 상기 화학식 1의 화합물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 그의 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 조성물은 원료에 대하여 15 중량부 이하, 바람직하게는 10 중량부 이하의 양으로 첨가된다. 그러나 건강 및 위생을 목적으로 장기간 섭취할 경우에는 상기 범위 이하의 함량을 포함할 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.When the compound of Chemical Formula 1 is used as a food additive, the compound of Chemical Formula 1 may be added as it is or may be used together with other food or food ingredients, and may be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, health or therapeutic treatment). Generally, the composition of the present invention is added in an amount of not more than 15 parts by weight, preferably not more than 10 parts by weight, based on the raw material, when the food or beverage is produced. However, in case of long-term ingestion for health and hygiene purposes, the active ingredient may be contained in an amount not exceeding the above range and there is no problem in terms of safety.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 또는 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of the food. Examples of the food to which the above substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, Alcoholic beverages, or vitamin complexes, and includes all health foods in a conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드; 말토스, 슈크로스와 같은 디사카라이드; 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드; 자일리톨, 소르비톨, 에리트리톨 등의 당알콜일 수 있다. 감미제는 타우마틴, 스테비아 추출물과 같은 천연 감미제; 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL 당 일반적으로 약 0.01 ∼ 0.04 g, 바람직하게는 약 0.02 ∼ 0.03 g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as additional components such as ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; Xylitol, sorbitol, erythritol, and the like. Sweeteners include natural sweeteners such as tau Martin and stevia extract; Synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 mL of the composition of the present invention.
상기 외에 본 발명의 건강식품은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산, 펙트산의 염, 알긴산, 알긴산의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올 또는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강식품은 천연 과일주스, 과일주스 음료, 또는 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 혼합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부당 0.01 ~ 0.1 중량부의 범위에서 선택되는 것이 일반적이다.
In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acid, protective colloid thickener, pH adjusting agent, Glycerin, an alcohol or a carbonating agent, and the like. In addition, the health food of the present invention may contain natural fruit juice, fruit juice drink, or pulp for the production of vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
이하, 본 발명을 실시예에 의해 상세히 설명한다. 단, 하기 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예에 한정되는 것은 아니다.
Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are illustrative of the present invention, and the present invention is not limited to the following examples.
참조예Reference Example 1: One: 보닐아세테이트(bornyl acetate)물질Bornyl acetate material 정보 Information
비시클로[2.2.1]헵탄-2-올, 1,7,7-트리메틸-, 아세테이트, (1S-엔도)-(Bicyclo[2.2.1]heptan-2-ol, 1,7,7-trimethyl-, acetate, (1S-endo)-)Bicyclo [2.2.1] heptan-2-ol, 1,7,7-trimethyl-, acetate, (1S-endo) - (Bicyclo [ -, acetate, (1S-endo) -)
CAS No.: 5655-61-8 CAS No .: 5655-61-8
구입처: sigma-aldrich korea
Where to buy: sigma-aldrich korea
실시예Example 1: 콜라겐 총량 증가 효과 1: Increase effect of total collagen
하기 표 1의 물질을 인간 유래 섬유아세포의 배양액에 첨가하여 세포수준에서 콜라겐 총량을 측정하였다. 콜라겐의 총량의 측정은 PICP EIA kit(Procollagen Type I C-Peptide Enzyme ImmunoAssay KIT)를 이용하여 정량하였다. 실험전 인간 유래 섬유아세포를 대상으로 실험물질의 농도 10ppm, 1ppm, 0.1ppm, 0.01 ppm, 0.001 ppm에서 세포독성을 평가(섬유아세포를 배양하여 MTT 시험을 하는 방법[참고문헌: Mossman T. (1983). Rapid Colorimetric Assay for Cellular Growth & Survival: application to proliferation & cytotoxicity assays. Journal of Immunological Methods 65, 55-63] 하였으며, 세포독성이 없는 농도를 선정하여 콜라겐 총량을 측정하였다. The substances in Table 1 below were added to the culture medium of human-derived fibroblasts and the total amount of collagen was measured at the cellular level. The total amount of collagen was quantitated using a PICP EIA kit (Procollagen Type I C-Peptide Enzyme Immunoassay Kit). To evaluate the cytotoxicity of human fibroblasts before experimentation at concentrations of 10 ppm, 1 ppm, 0.1 ppm, 0.01 ppm, and 0.001 ppm of the test substance (method for MTT test by culturing fibroblasts [Reference: Mossman T. ), And the total amount of collagen was measured by selecting a concentration without cytotoxicity. The results are shown in Table 1.
실험에서 화학식 1의 화합물의 최종 농도는 각각 1 ppm, 10 ppm으로 하였으며, 각각의 시료는 인간 섬유아세포의 배양배지에 첨가하여 1일간 배양한 후, 배양액을 취하여 PICP EIA 키트로 각 농도에서의 콜라겐 총량을 분광광도계를 이용하여 450 nm에서 측정하였다. 효과의 비교를 위하여 아무것도 첨가하지 않은 섬유아세포의 배양 배지(대조군)와 비타민 C를 최종 농도 52.8 ppm이 되도록 첨가한 시료에 대하여 동일한 방법으로 콜라겐 총량을 측정하였다. 콜라겐 총량은 UV 흡광도로서 측정하였으며, 콜라겐 총량의 증가율은 대조군에 대한 상대적인 콜라겐 총량 비율로 계산하고, 그 결과를 하기 표 1에 정리하였다.In the experiment, the final concentrations of the compounds of Chemical Formula 1 were 1 ppm and 10 ppm, respectively. Each sample was added to the culture medium of human fibroblasts and cultured for 1 day. Then, the culture broth was taken and the collagen The total amount was measured at 450 nm using a spectrophotometer. For the comparison of the effects, the total amount of collagen was measured by the same method for the culture medium of the fibroblasts to which nothing was added (control group) and the sample added with vitamin C to the final concentration of 52.8 ppm. The total amount of collagen was measured as a UV absorbance, and the rate of increase of the total amount of collagen was calculated by the ratio of the total amount of collagen relative to the control, and the results are summarized in Table 1 below.
(1 ppm)The compound of formula (1)
(1 ppm)
(10 ppm)The compound of formula (1)
(10 ppm)
(무첨가)Control group
(No additives)
(52.8 ppm)Vitamin C
(52.8 ppm)
상기 표 1의 결과에서 볼 수 있듯이, 화학식 1의 화합물(10 ppm)은 콜라겐 합성 능력이 있는 것으로 알려진 비타민 C(52.8ppm)를 적용한 경우보다 그 활성은 낮으나, 천연물질로써 우수한 수준의 콜라겐 합성능과 함께 안정하다. 따라서, 화학식 1의 화합물은 피부 재생, 주름개선을 위한 용도로 사용할 수 있음을 알 수 있다.
As shown in the results of Table 1, the compound of formula (1) (10 ppm) has lower activity than that of vitamin C (52.8 ppm), which is known to have the ability to synthesize collagen, . Therefore, it can be seen that the compound of Chemical Formula 1 can be used for skin regeneration and wrinkle improvement.
실시예Example 2: 멜라닌 총량 감소 효과 2: Reduction effect of total melanin
쥐의 멜라노마 세포(B-16 mouse melanoma cell)의 배양액에 첨가하여, 세포 수준에서의 멜라닌 총량을 측정함으로써, 미백 효과를 학인하였다(Lotan R., Lotan D. Cancer Res. 40:3345-3350, 1980). 실험 전 쥐의 멜라노마 세포에 대하여 독성을 평가하여 독성이 없는 농도를 선정하여 미백평가를 수행하였다.(Lotan R., Lotan D. Cancer Res. 40: 3345-3350). In addition, the present inventors have found that the whitening effect can be measured by measuring the total amount of melanin at the cellular level by adding the resultant to a culture medium of mouse B-16 mouse melanoma cells , 1980). To evaluate the toxicity of melanoma cells in rats before the experiment, whitening evaluation was performed by selecting a concentration that is not toxic.
화학식1의 화합물을 배양액에 최종농도가 5 ppm, 10 ppm, 20 ppm 이 되도록 하였으며, 대조군인 알부틴은 200 ppm 이 되도록 배지에 첨가하여 각각 B-16 멜라노마 세포에 처리하여 3일간 배양하였다. The compound of formula (I) was added to the culture medium to give final concentrations of 5 ppm, 10 ppm, and 20 ppm, and the control group, arbutin, was added to the medium to 200 ppm, followed by treatment with B-16 melanoma cells for 3 days.
이후, 세포들을 트립신(trypsin)처리하여 배양용기로부터 떼어내 원심분리 한 후 멜라닌을 추출하였다. 떼어낸 세포는 수산화 나트륨 용액(1N농도) 1ml를 가하여 10분간 끓여 멜라닌을 녹이고 분광 광도계를 이용하여, 400나노미터(nm)에서 흡광도를 측정하여 생성된 멜라닌의 양을 측정하였다. Cells were then trypsinized, detached from the culture, centrifuged, and extracted with melanin. The removed cells were melted with 1 ml of sodium hydroxide solution (1N concentration), boiled for 10 minutes, melanin was dissolved, and the amount of melanin produced by measuring the absorbance at 400 nanometers (nm) was measured using a spectrophotometer.
상기 멜라닌 양은 단위 세포수당(106 cell)의 흡광도로 나타내는 방법으로 측정하였으며, 대조군에 대한 상대적인 멜라닌 총량을 저해율(%)로 계산하고 결과를 표 2에 정리하였다. 실험은 3번 반복된 것이다.The amount of melanin was measured by an absorbance of 10 6 cells per unit cell, and the total amount of melanin relative to the control group was calculated as inhibition (%). The results are summarized in Table 2. The experiment was repeated three times.
표 2에 나타난 바와 같이, 화학식 1의 화합물은 미백 물질로 알려진 알부틴(200 ppm)과 비교할 때, 적은 농도에서 배양된 쥐의 멜라노마 세포에 대하여 멜라닌 총량이 유사하게 감소하여 미백 용도로 사용할 수 있음을 알 수 있었다.
As shown in Table 2, the compound of the formula (1) can be used for whitening purposes because the total amount of melanin is similarly reduced with respect to melanoma cells of mice cultured at a low concentration, as compared with arbutin (200 ppm) known as a whitening substance And it was found.
실시예Example 3: 항산화 효과- 3: Antioxidant effect - 자유라디칼Free radical 소거율 Erasure rate
항산화 작용을 확인하기 위해 자유라디칼 소거 활성을 측정하였다. 자유라디칼 소거 활성은 DPPH를 이용하여 측정하였다. DPPH는 시그마사(Sigma Co., Ltd, 미국)에서 구입하여 사용하였다. 먼저, 1.5 mM(0.06 mg/mL) 농도의 표준 DPPH 에탄올 용액을 만들었다. 그리고 화학식 1의 화합물과 기준물질로 항산화제인 아스코르빈산에 각각 에탄올을 가하여 50 ppm, 25 ppm, 12.5 ppm, 6.25 ppm, 3.125 ppm 의 농도로 시료를 만들었다. 그 다음, 상기 시료와 표준 DPPH 용액을 같은 비율로 첨가하여 잘 교반한 후, 37 ℃에서 30 분간 반응시키고 520 ㎚에서 흡광도를 측정하였다. 이때, 상기 시료 대신 에탄올을 첨가한 것을 대조군으로 하였다. 자유라디칼 소거능은 half maximal inhibitory concentration(억제중간값)인 IC50을 구하여 그 결과를 하기 표 3에 나타내었다. IC50은 무첨가 대조군의 자유라디칼을 50% 제거하는데 필요한 아스코르빈산 및 화학식 1의 화합물의 농도로써 자유라디칼 소거능을 표현하는 일반적인 방법이다.Free radical scavenging activity was measured to confirm antioxidant activity. Free radical scavenging activity was measured using DPPH. DPPH was purchased from Sigma Co. (Sigma Co., Ltd., USA) and used. First, a standard DPPH ethanol solution at a concentration of 1.5 mM (0.06 mg / mL) was prepared. Then, ethanol was added to the ascorbic acid, which is an antioxidant, as a reference compound and the compound of Chemical Formula 1, respectively, to prepare samples at concentrations of 50 ppm, 25 ppm, 12.5 ppm, 6.25 ppm, and 3.125 ppm. Then, the sample and standard DPPH solution were added at the same ratio, stirred well, reacted at 37 ° C for 30 minutes, and absorbance was measured at 520 nm. At this time, ethanol was added instead of the sample to give a control group. The IC 50 , half maximal inhibitory concentration, was determined for the free radical scavenging ability, and the results are shown in Table 3 below. IC 50 is a common method of expressing free radical scavenging activity with the concentration of ascorbic acid and the compound of formula 1 required to remove 50% of the free radicals of the no-added control group.
상기 표 3에서 알 수 있듯이, 화학식 1의 화합물은 대표적인 강력한 항산화물질인 아스코르빈산(Vitamin C)에 비해, 그 활성은 낮으나, 천연물질로써 우수한 수준의 항산화 효과와 함께 안정하여 항산화 효능 물질로 사용하기 적합함을 알 수 있다.
As can be seen from the above Table 3, the compound of formula (I) is less active than ascorbic acid (Vitamin C), which is a typical strong antioxidant, but is stable as an antioxidant It can be seen that it is suitable for the following.
실시예Example 4: 항염증 효과- 4: Anti-inflammatory effect - NONO 생성 억제 효과 Production inhibitory effect
항염증 효과 및 피부트러블 완화 효과를 확인하기 위하여, RAW264.7 세포주 (ATCC number: CRL-2278)를 이용한 GRIESS 법으로 nitric oxide(NO) 형성억제력 실험을 실시하였다.In order to confirm the anti-inflammatory effect and skin tear-reducing effect, nitric oxide (NO) formation inhibition experiment was performed by GRIESS using RAW264.7 cell line (ATCC number: CRL-2278).
구체적으로, 생쥐의 대식세포인 RAW264.7 세포를 수차례 계대배양하고, 웰 하나에 3×105 개씩 들어가도록 24-웰 프레이트에 넣은 후, 24 시간 동안 배양시켰다. 이어서, 1%, 0.1%, 0.01%, 0.001% 농도로 화학식 1의 화합물을 희석하여 함유한 세포 배지로 교체하였다. 이때, NO-생성 억제물질인 L-NMMA(L-NG-Monomethylarginine) 0.001%를 양성 대조군으로 함께 처리하여 30분 동안 배양하였고, 자극원으로 LPS(Lipopolysaccharide)를 1 μg씩 처리하여 24시간 동안 배양하였다. 상층액을 100 μl씩 취해 96-웰 프레이트에 옮기고, GRIESS 용액을 100 μl씩 가해 상온에서 10분간 반응시키고, 540nm에서의 흡광도를 측정함으로써 화학식 1의 화합물의 NO 억제 효과를 판단하고, 그 결과를 하기 표 4에 나타내었다.Specifically, RAW264.7 cells, macrophages of mice, were subcultured several times, placed in 24-well plates at 3 × 10 5 per well, and cultured for 24 hours. Subsequently, the cell culture medium containing the compound of formula (1) was diluted with the concentrations of 1%, 0.1%, 0.01% and 0.001%. At this time, 0.001% of L-NMMA (L-NG-Monomethylarginine), which is an inhibitor of NO production, was treated with a positive control and cultured for 30 minutes. Lipopolysaccharide (LPS) Respectively. 100 μl of the supernatant was transferred to a 96-well plate, and 100 μl of the GRIESS solution was added thereto at room temperature for 10 minutes. The absorbance at 540 nm was measured to determine the NO inhibitory effect of the compound of formula (1) Are shown in Table 4 below.
표 4에서 알 수 있듯이, 화학식 1의 화합물은 대표적인 항염 의약물질인 L-NMMA와 비교하였을 때, 그 활성은 낮으나 천연물질로써 우수한 활성을 나타내어, 미백 또는 주름 개선에 있어, 항염 효과가 보조적인 역할로 작용하여 상승효과를 기대할 수 있다.
As can be seen from Table 4, the compound of formula (I) exhibits excellent activity as a natural substance when compared with L-NMMA, which is a representative anti-inflammatory drug, and its activity is low, and anti-inflammatory effect is supplementary in whitening or wrinkle improvement And a synergistic effect can be expected.
제제예Formulation example 1: 약학적 제제의 제조 1: Preparation of pharmaceutical preparations
1. 산제의 제조1. Manufacturing of powder
화학식 1의 화합물 0.001g0.001 g of the compound of formula (1)
유당 1g Lactose 1g
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
The above components were mixed and packed in airtight bags to prepare powders.
2. 정제의 제조2. Preparation of tablets
화학식 1의 화합물 0.2㎎ 0.2 mg of the compound of formula (1)
옥수수전분 100㎎ 100 mg of corn starch
유 당 100㎎ 100 mg of milk
스테아린산Stearic acid 마그네슘 2㎎ Magnesium 2 mg
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
3. 캡슐제의 제조3. Preparation of capsules
화학식 1의 화합물 0.2㎎ 0.2 mg of the compound of formula (1)
옥수수전분 100㎎ 100 mg of corn starch
유 당 100㎎ 100 mg of milk
스테아린산Stearic acid 마그네슘 2㎎ Magnesium 2 mg
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.
4. 환의 제조4. Manufacture of rings
화학식 1의 화합물 0.003 g 0.003 g of the compound of formula (1)
유당 1.5 g Lactose 1.5 g
글리세린 1 g Glycerin 1 g
자일리톨Xylitol 0.5 g 0.5 g
상기의 성분을 혼합한 후, 통상의 방법에 따라 1 환 당 4 g이 되도록 제조하였다.
After mixing the above components, they were prepared so as to be 4 g per one ring according to a conventional method.
5. 과립의 제조5. Manufacture of granules
화학식 1의 화합물 2 ㎎ 2 mg of the compound of formula (1)
대두 추출물 50 ㎎ Soybean extract 50 mg
포도당 200 ㎎ 200 mg of glucose
전분 600 ㎎ 600 mg of starch
상기의 성분을 혼합한 후, 30% 에탄올 100 ㎎을 첨가하여 60℃에서 건조하여 과립을 형성한 후 포에 충진하였다.
After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 캜 to form granules, which were then filled in a capsule.
제제예Formulation example 2: 화장품의 제조 2: Manufacture of cosmetics
1. 유연화장수(스킨로션)의 제조1. Manufacture of softening longevity (skin lotion)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 유연화장수를 통상의 방법에 따라 제조하였다.As the following composition, the number of softening times containing the compound of formula (1) as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.1 중량％0.1% by weight of the compound of formula (1)
베타-1,3-글루칸 1.0 중량％Beta-1,3-glucan 1.0 wt%
부틸렌글리콜 2.0 중량％Butylene glycol 2.0 wt%
프로필렌글리콜 2.0 중량％Propylene glycol 2.0 wt%
카르복시비닐폴리머 0.1 중량％Carboxyvinyl polymer 0.1 wt%
피이지-12 노닐페닐에테르 0.2 중량％0.2% by weight of phage-12 nonylphenyl ether
폴리솔베이트80 0.4 중량％Polysorbate 80 0.4 wt%
에탄올 10.0 중량％Ethanol 10.0 wt%
트리에탄올아민 0.1 중량％0.1% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수 to 100 중량％
Purified water to 100%
2. 영양화장수(밀크로션)의 제조2. Manufacture of nutrition lotion (milk lotion)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 영양화장수를 통상의 방법에 따라 제조하였다.As in the following composition, a nutritional lotion containing the compound of the formula (1) as an active ingredient was prepared by a conventional method.
화학식 1의 화합물 0.1 중량％0.1% by weight of the compound of formula (1)
베타-1,3-글루칸 1.0 중량％Beta-1,3-glucan 1.0 wt%
밀납 4.0 중량％4.0 wt%
폴리솔베이트60 1.5 중량％Polysorbate 60 1.5 wt%
솔비탄세스퀴올레이트 1.5 중량％1.5% by weight of sorbitan sesquioleate
유동파라핀 0.5 중량％0.5% by weight liquid paraffin
카프릴릭/카프릭트리글리세라이드 5.0 중량％Caprylic / capric triglyceride 5.0 wt%
글리세린 3.0 중량％Glycerin 3.0 wt%
부틸렌글리콜 3.0 중량％3.0% by weight of butylene glycol
프로필렌글리콜 3.0 중량％3.0% by weight of propylene glycol
카르복시비닐폴리머 0.1 중량％Carboxyvinyl polymer 0.1 wt%
트리에탄올아민 0.2 중량％0.2% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수 to 100 중량％
Purified water to 100%
3. 영양크림의 제조3. Manufacture of nutritional cream
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 영양크림을 통상의 방법에 따라 제조하였다.A nutritional cream containing the compound of formula (1) as an active ingredient was prepared according to a conventional method, as shown below.
화학식 1의 화합물 0.2중량％0.2% by weight of the compound of formula (1)
베타-1,3-글루칸 5.0 중량％Beta-1,3-glucan 5.0 wt%
밀납 10.0 중량％Wax 10.0 wt%
폴리솔베이트60 1.5 중량％Polysorbate 60 1.5 wt%
피이지 60 경화피마자유 2.0 중량％≪ tb > < tb > < tb >
솔비탄세스퀴올레이트 0.5 중량％0.5% by weight of sorbitan sesquioleate
유동파라핀 10.0 중량％Liquid paraffin 10.0 wt%
스쿠알란 5.0 중량％Squalane 5.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량％Caprylic / capric triglyceride 5.0 wt%
글리세린 5.0 중량％Glycerin 5.0 wt%
부틸렌글리콜 3.0 중량％3.0% by weight of butylene glycol
프로필렌글리콜 3.0 중량％3.0% by weight of propylene glycol
트리에탄올아민 0.2 중량％0.2% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수 to 100 중량％
Purified water to 100%
4. 마사지크림의 제조4. Manufacture of massage cream
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 마사지크림을 통상의 방법에 따라 제조하였다.A massage cream containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.
화학식 1의 화합물 0.1 중량％0.1% by weight of the compound of formula (1)
베타-1,3-글루칸 3.0 중량％Beta-1,3-glucan 3.0 wt%
밀납 10.0 중량％Wax 10.0 wt%
폴리솔베이트60 1.5 중량％Polysorbate 60 1.5 wt%
피이지 60 경화피마자유 2.0 중량％≪ tb > < tb > < tb >
솔비탄세스퀴올레이트 0.8 중량％0.8% by weight of sorbitan sesquioleate
유동파라핀 40.0 중량％Liquid paraffin 40.0 wt%
스쿠알란 5.0 중량％Squalane 5.0 wt%
카프릴릭/카프릭트리글리세라이드 4.0 중량％Caprylic / capric triglyceride 4.0 wt%
글리세린 5.0 중량％Glycerin 5.0 wt%
부틸렌글리콜 3.0 중량％3.0% by weight of butylene glycol
프로필렌글리콜 3.0 중량％3.0% by weight of propylene glycol
트리에탄올아민 0.2 중량％0.2% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수 to 100 중량％
Purified water to 100%
5. 팩의 제조5. Manufacture of pack
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 팩을 통상의 방법에 따라 제조하였다.A pack containing the compound of formula (1) as an active ingredient was prepared according to a conventional method, as shown below.
화학식 1의 화합물 0.2 중량％0.2% by weight of the compound of formula (1)
베타-1,3-글루칸 1.0 중량％Beta-1,3-glucan 1.0 wt%
폴리비닐알콜 13.0 중량％Polyvinyl alcohol 13.0 wt%
소듐카르복시메틸셀룰로오스 0.2 중량％0.2% by weight of sodium carboxymethylcellulose,
글리세린 5.0 중량％Glycerin 5.0 wt%
알란토인 0.1 중량％Allantoin 0.1 wt%
에탄올 6.0 중량％6.0% by weight of ethanol
피이지 -12 노닐페닐에테르 0.3 중량％0.3% by weight of phage-12 nonylphenyl ether
폴리솔베이트 60 0.3 중량％Polysorbate 60 0.3 wt%
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수 to 100 중량％
Purified water to 100%
제제예Formulation example 3: 3: 피부외용제의Topical 제조 Produce
1. 젤의 제조1. Manufacture of gel
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 젤을 통상의 방법에 따라 제조하였다.As in the following composition, a gel containing the compound of formula (1) as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.1 중량％0.1% by weight of the compound of formula (1)
베타-1,3-글루칸 0.1 중량％0.1% by weight of beta-1,3-glucan
에틸렌디아민초산나트륨 0.05 중량％0.05% by weight of sodium ethylenediaminetetraacetate
글리세린 5.0 중량％Glycerin 5.0 wt%
카르복시비닐폴리머 0.3 중량％Carboxyvinyl polymer 0.3 wt%
에탄올 5.0 중량％5.0% by weight of ethanol
피이지-60 경화피마자유 0.5 중량％≪ tb > < tb > < tb >
트리에탄올아민 0.3 중량％Triethanolamine 0.3 wt%
방부제 0.05 중량％ Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수 to 100 중량％
Purified water to 100%
2. 연고의 제조2. Manufacture of ointment
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 연고를 통상의 방법에 따라 제조하였다.An ointment containing the compound of formula (I) as an active ingredient was prepared according to a conventional method, as shown below.
화학식 1의 화합물 0.5 중량％0.5% by weight of the compound of formula (1)
베타-1,3-글루칸 10.0 중량%Beta-1,3-glucan 10.0 wt%
밀납 10.0 중량%Wax 10.0 wt%
폴리솔베이트60 5.0 중량%Polysorbate 60 5.0 wt%
피이지 60 경화피마자유 2.0 중량%≪ tb > < tb > < tb >
솔비탄세스퀴올레이트 0.5 중량%0.5% by weight of sorbitan sesquioleate
바셀린 5.0 중량%Vaseline 5.0 wt%
유동파라핀 10.0 중량%Liquid paraffin 10.0 wt%
스쿠알란 5.0 중량%Squalane 5.0 wt%
쉐어버터 3.0 중량%SHARE BUTTER 3.0 wt%
카프릴릭/카프릭트리글리세라이드 5.0 중량%Caprylic / capric triglyceride 5.0 wt%
글리세린 10.0 중량%Glycerin 10.0 wt%
프로필렌글리콜 10.2 중량%Propylene glycol 10.2 wt%
트리에탄올아민 0.2 중량%0.2% by weight triethanolamine
방부제 0.05 중량％Preservative 0.05 wt%
색소 0.05 중량％0.05% by weight of pigment
향료 0.05 중량％0.05% by weight fragrance
정제수 to 100 중량%
Purified water to 100%
3. 국소투여용 약제(겔 연고제) 의 제조3. Preparation of topical medicament (gel ointment)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 겔 연고제를 통상의 방법에 따라 제조하였다.A gel ointment agent containing the compound of the formula (1) as an active ingredient was prepared according to a conventional method.
화학식 1의 화합물 0.5 중량％0.5% by weight of the compound of formula (1)
베타-1,3-글루칸 10.0 중량%Beta-1,3-glucan 10.0 wt%
폴리아크릴산(Carbopol 940) 1.5 중량%1.5% by weight of polyacrylic acid (Carbopol 940)
이소프로판올 5.0 중량%5.0% by weight of isopropanol
헥실렌글리콜 25.0 중량%Hexylene glycol 25.0 wt%
트리에탄올아민 1.7 중량%Triethanolamine 1.7 wt%
탈이온수 to 100 중량%
Deionized water to 100%
4. 국소 투여용 약제(패취제)의 제조4. Preparation of topical medicines (patches)
하기 조성과 같이, 화학식 1의 화합물을 유효성분으로 포함하는 패취제를 통상의 방법에 따라 제조하였다.As the following composition, a patch containing a compound of the formula (1) as an active ingredient was prepared by a conventional method.
화학식 1의 화합물 0.5 중량%0.5% by weight of the compound of formula (1)
베타-1,3-글루칸 3.0 중량%Beta-1,3-glucan 3.0 wt%
헥실렌글리콜 20.0 중량% Hexylene glycol 20.0 wt%
디에틸아민 0.7 중량%Diethylamine 0.7 wt%
폴리아크릴산(Carbopol 934P) 1.0 중량%1.0% by weight of polyacrylic acid (Carbopol 934P)
아황산나트륨 0.1 중량%0.1% by weight of sodium sulfite
폴리옥시에틸렌라우릴에테르(E.O=9) 1.0 중량%1.0% by weight of polyoxyethylene lauryl ether (E.O. = 9)
폴리히드록시에틸렌세틸스테아릴에테르(Cetomacrogol 1000) 1.0 중량%1.0% by weight of polyhydroxyethylene cetyl stearyl ether (Cetomacrogol 1000)
점성의 파라핀 오일 2.5 중량%Viscous paraffin oil 2.5 wt%
카프릴산에스테르/카프르산에스테르(Cetiol LC) 2.5 중량%2.5% by weight of caprylic acid ester / capric acid ester (Cetiol LC)
폴리에틸렌글리콜400 3.0 중량%Polyethylene glycol 400 3.0 wt%
탈이온수 to 100 중량%
Deionized water to 100%
제제예Formulation example 4: 식품의 제조 4: Manufacturing of food
본 발명의 화학식 1의 화합물을 포함하는 식품들을 다음과 같이 제조하였다.Foods containing the compound of formula (I) of the present invention were prepared as follows.
1. 밀가루 식품의 제조1. Manufacture of Flour Food
상기 화학식 1의 화합물 0.05 ~ 1.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강식품을 제조하였다.
0.05 to 1.0 part by weight of the compound of Formula 1 was added to wheat flour, and a bread, a cake, a cookie, a cracker and a noodle were prepared using the mixture to prepare a health food.
2. 유제품(dairy products)의 제조2. Manufacture of dairy products
상기 화학식 1의 화합물 0.2 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.
0.2 part by weight of the compound of Formula 1 was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.
3. 선식의 제조3. Manufacturing of wire
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다. 검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다. 상기 화학식 1의 화합물을 진공 농축기에서 감압농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh. Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer. The compound of Formula 1 was concentrated under reduced pressure in a vacuum concentrator, sprayed, and dried with a hot-air drier, and the resulting dried product was pulverized to a size of 60 mesh with a pulverizer to obtain a dried powder.
상기에서 제조한 곡물류, 종실류 및 화학식 1의 화합물의 건조분말을 혼합 분말 100 중량부에 대하여 다음의 비율로 배합하여 제조하였다.The grains, seeds, and dry powder of the compound of formula (1) prepared above were blended in the following proportions relative to 100 parts by weight of the mixed powder.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),(30 parts by weight of brown rice, 15 parts by weight of yulmu, 20 parts by weight of barley)
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
화학식 1의 화합물(0.1 중량부),(1) (0.1 part by weight),
영지(0.5 중량부),(0.5 part by weight),
지황(0.5 Rhubarb (0.5
중량부Weight portion
) )
제제예Formulation example 5: 음료의 제조 5: Manufacture of beverages
1. 건강음료의 제조1. Manufacture of health drinks
화학식 1의 화합물 0.1 ㎎ 0.1 mg of the compound of formula (1)
구연산 1000 ㎎ Citric acid 1000 mg
올리고당 100 g 100 g of oligosaccharide
매실농축액 2 g Plum concentrate 2 g
타우린 1 g Taurine 1 g
정제수를Purified water 가하여 전체 900 All 900 mLmL
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1 시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2L-용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용하였다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring. Then, the solution thus prepared was filtered and sterilized in a sterilized 2L-container, Lt; RTI ID = 0.0 > health < / RTI >
상기 조성비는 비교적 기호 음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
2. 야채주스의 제조2. Manufacture of vegetable juice
본 발명의 화학식 1의 화합물 1g을 토마토 또는 당근 주스 1,000mL에 가하여 건강 증진용 야채주스를 제조하였다.
1 g of the compound of formula (I) of the present invention was added to 1,000 mL of tomato or carrot juice to prepare vegetable juice for health promotion.
3. 과일주스의 제조3. Manufacture of fruit juice
화학식 1의 화합물 1 g을 사과 또는 포도 주스 1,000 mL에 가하여 건강 증진용 과일주스를 제조하였다.
1 g of the compound of formula (1) was added to 1,000 mL of apple or grape juice to prepare fruit juice for health promotion.
Claims (24)
[화학식 1]
A pharmaceutical composition for skin regeneration or wrinkle improvement comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
[화학식 1]
A skin external preparation for skin regeneration or wrinkle improvement comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
상기 외용제는 연고, 패취, 겔, 크림 또는 분무제의 제형인 피부 재생 또는 주름 개선용 피부 외용제.
3. The method of claim 2,
Wherein the external preparation is a formulation of ointment, patch, gel, cream or spray, which is used for skin regeneration or wrinkle improvement.
[화학식 1]
A cosmetic composition for skin regeneration or wrinkle improvement comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션 또는 세정제의 제형인 피부 재생 또는 주름 개선용 화장료 조성물.
5. The method of claim 4,
A cosmetic composition for skin regeneration or wrinkle improvement, which is a formulation of lotion, essence, lotion, cream, pack, gel, powder, foundation or detergent.
[화학식 1]
A health food for skin regeneration or wrinkle improvement comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
[화학식 1]
A pharmaceutical composition for antioxidation comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
[화학식 1]
An external skin preparation for antioxidation comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
상기 외용제는 연고, 패취, 겔, 크림 또는 분무제의 제형인 항산화용 피부 외용제.
9. The method of claim 8,
Wherein said external preparation is a formulation of ointment, patch, gel, cream or spray.
[화학식 1]
A cosmetic composition for antioxidation comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션 또는 세정제의 제형인 항산화용 화장료 조성물.
11. The method of claim 10,
Cosmetics, essences, lotions, creams, packs, gels, powders, foundations or detergents.
[화학식 1]
An antioxidant health food containing the compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
[화학식 1]
An antiinflammatory pharmaceutical composition comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
[화학식 1]
An antiinflammatory skin external preparation comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
상기 외용제는 연고, 패취, 겔, 크림 또는 분무제의 제형인 항염증용 피부 외용제.
15. The method of claim 14,
Wherein said external preparation is a formulation of ointment, patch, gel, cream or spray.
[화학식 1]
An anti-inflammatory cosmetic composition comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션 또는 세정제의 제형인 항염증용 화장료 조성물.
17. The method of claim 16,
Cosmetics, essences, lotions, creams, packs, gels, powders, foundations or detergents.
[화학식 1]
An anti-inflammatory health food containing the compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
[화학식 1]
A pharmaceutical composition for skin whitening comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
[화학식 1]
An external skin preparation for skin whitening comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
상기 외용제는 연고, 패취, 겔, 크림 또는 분무제의 제형인 미백용 피부 외용제.
21. The method of claim 20,
Wherein the external preparation is a formulation of ointment, patch, gel, cream or spray.
[화학식 1]
A cosmetic composition for skin whitening comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
화장수, 에센스, 로션, 크림, 팩, 젤, 파우더, 파운데이션 또는 세정제의 제형인 미백용 화장료 조성물.
23. The method of claim 22,
Wherein the cosmetic composition is a formulation of a lotion, essence, lotion, cream, pack, gel, powder, foundation or detergent.
[화학식 1]
A health food for skin whitening comprising a compound represented by the following formula (1) as an active ingredient:
[Chemical Formula 1]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130141527A KR102059852B1 (en) | 2013-11-20 | 2013-11-20 | Cosmetic composition containing Oriental Herb Fragrance Active Component Bornyl Acetate for Skin Benefit Ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130141527A KR102059852B1 (en) | 2013-11-20 | 2013-11-20 | Cosmetic composition containing Oriental Herb Fragrance Active Component Bornyl Acetate for Skin Benefit Ingredient |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190169747A Division KR20200003357A (en) | 2019-12-18 | 2019-12-18 | Cosmetic composition containing Oriental Herb Fragrance Active Component Bornyl Acetate for Skin Benefit Ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150057764A true KR20150057764A (en) | 2015-05-28 |
| KR102059852B1 KR102059852B1 (en) | 2019-12-27 |
Family
ID=53392561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130141527A KR102059852B1 (en) | 2013-11-20 | 2013-11-20 | Cosmetic composition containing Oriental Herb Fragrance Active Component Bornyl Acetate for Skin Benefit Ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102059852B1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011102245A (en) * | 2009-11-10 | 2011-05-26 | Zecfield:Kk | Extract of fir tree |
-
2013
- 2013-11-20 KR KR1020130141527A patent/KR102059852B1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011102245A (en) * | 2009-11-10 | 2011-05-26 | Zecfield:Kk | Extract of fir tree |
Non-Patent Citations (2)
| Title |
|---|
| Bioresource Technology, 99(9), 3908-3913(2008.06.30.) 1부.* * |
| International Journal of Cosmetic Science, 35, 484-490(2013.05.29.) 1부.* * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102059852B1 (en) | 2019-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20150057898A (en) | Composition for skin cell regeneration, anti-wrinkle, anti-imflamation, and skin whitening | |
| KR20150019566A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR102000520B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR101977867B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR101999698B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR20150057765A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component Trans-Caryophyllene for Skin Benefit Ingredient | |
| KR20150057763A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component Tridecane for Skin Benefit Ingredient | |
| KR20150057759A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component Limonene for Skin Benefit Ingredient | |
| KR20150057757A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component Sabinene for Skin Benefit Ingredient | |
| KR101989012B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR101991432B1 (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR20150019574A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR20150019677A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR20150019578A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR20150019626A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR20150019625A (en) | Composition for skin cell regeneration, anti-wrinkle, antioxidant, anti-imflamation, and skin whitening | |
| KR20150057764A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component Bornyl Acetate for Skin Benefit Ingredient | |
| KR20150057766A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component Valencene for Skin Benefit Ingredient | |
| KR20150057767A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component 8-heptadecene for Skin Benefit Ingredient | |
| KR20150057762A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component Estragole for Skin Benefit Ingredient | |
| KR20150058706A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component L-menthone for Skin Benefit Ingredient | |
| KR20150057760A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component Terpinolene for Skin Benefit Ingredient | |
| KR20150057761A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component alpha-fenchone for Skin Benefit Ingredient | |
| KR20150057756A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component Camphene for Skin Benefit Ingredient | |
| KR20150057758A (en) | Cosmetic composition containing Oriental Herb Fragrance Active Component Alpha-Terpinene for Skin Benefit Ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| A107 | Divisional application of patent |